{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T08:05:34Z","timestamp":1762675534666,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC1561"],"award-info":[{"award-number":["2024NSFSC1561"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118211","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:17:06Z","timestamp":1759731426000},"page":"118211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of a novel benzyloxy-terminated scaffold as a potent and selective TYK2 inhibitor for anti-inflammatory therapy"],"prefix":"10.1016","volume":"301","author":[{"given":"Yang","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengkang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-9907","authenticated-orcid":false,"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118211_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118211_bib2","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1021\/acs.jmedchem.8b00667","article-title":"Kinase inhibitors for the treatment of immunological disorders: recent advances","volume":"61","author":"Bryan","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118211_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.181.1.399","article-title":"Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12","volume":"181","author":"Bacon","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118211_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2025.118211_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2025.118211_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115611","article-title":"Discovery of WD-890: a novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases","volume":"167","author":"Fang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118211_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","article-title":"Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)","volume":"29","author":"He","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.118211_bib9","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1021\/jm400266t","article-title":"Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors","volume":"56","author":"Liang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib10","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib11","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2665-9913(20)30397-0","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study","volume":"3","author":"Tehlirian","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ejmech.2025.118211_bib12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/13543784.2024.2391825","article-title":"Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis","volume":"33","author":"Liu","year":"2024","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118211_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118211_bib15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118211_bib16","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ejmech.2025.118211_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70094","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design","volume":"17","author":"Ucpinar","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.118211_bib18","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118211_bib19","doi-asserted-by":"crossref","first-page":"8991","DOI":"10.1073\/pnas.160130297","article-title":"A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-\u03b1 signaling","volume":"97","author":"Yeh","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118211_bib20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1039\/C6MD00560H","article-title":"Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling","volume":"8","author":"Moslin","year":"2017","journal-title":"MedChemComm"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118211_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118211_bib22","first-page":"354","article-title":"Brepocitinib, a potent and selective TYK2\/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis","volume":"43","author":"Paik","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118211_bib23","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/13543784.2024.2391825","article-title":"Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis","volume":"33","author":"Liu","year":"2024","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118211_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljaf185","article-title":"Safety and efficacy of the selective TYK2\/JAK1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase 1b, randomized, double-blind, placebo-controlled study","author":"Chen","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118211_bib25","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1021\/acs.jmedchem.1c01137","article-title":"Identification of a novel 2,8-Diazaspiro[4.5]decan-1-one derivative as a potent and selective dual TYK2\/JAK1 inhibitor for the treatment of inflammatory bowel disease","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib26","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/jm1011319","article-title":"Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak\/Stat pathway","volume":"54","author":"Ioannidis","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib28","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective inhibitor: functional differentiation of JAK3-Selective inhibition over pan-JAK or JAK1-Selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118211_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118211_bib30","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118211_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155552","article-title":"STAT1 N-terminal domain discriminatively controls type I and type II IFN signaling","volume":"144","author":"Goder","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.ejmech.2025.118211_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ejmech.2025.118211_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis - 2023","volume":"13","author":"Wise","year":"2023","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.ejmech.2025.118211_bib34","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/all.14586","article-title":"Advances and novel developments in allergic rhinitis","volume":"75","author":"Meng","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2025.118211_bib35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaci.2022.01.016","article-title":"Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma","volume":"149","author":"Shamji","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2025.118211_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.118211_bib37","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2024.0530","article-title":"Allergic rhinitis: a review","volume":"331","author":"Bernstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118211_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2025.118211_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568630","article-title":"IL-12-Induced immune suppressive deficit during CD8+ T-Cell differentiation","volume":"11","author":"Renavikar","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118211_bib40","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230683","article-title":"TCR signaling induces STAT3 phosphorylation to promote TH17 cell differentiation","volume":"221","author":"Qin","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118211_bib41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11596-007-0329-1","article-title":"Expression of Th17 cytokines in skin lesions of patients with psoriasis","volume":"27","author":"Jiawen","year":"2007","journal-title":"J. Huazhong Univ. Sci. Technol."},{"key":"10.1016\/j.ejmech.2025.118211_bib42","first-page":"323","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease, Nature reviews","volume":"17","author":"Salas","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118211_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112256","article-title":"Inhibitory effect of phellodendrine on C48\/80-induced allergic reaction in vitro and in vivo","volume":"134","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.118211_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/ph16010047","article-title":"A novel mast cell stabilizer JM25-1 rehabilitates impaired gut barrier by targeting the corticotropin-releasing hormone receptors","volume":"16","author":"Sun","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118211_bib45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41590-020-0758-6","article-title":"The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation","volume":"21","author":"Ng","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2025.118211_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111944","article-title":"Anti-allergic effects of Asarum heterotropoides on an ovalbumin-induced allergic rhinitis murine model","volume":"141","author":"Choi","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118211_bib47","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jaci.2020.12.644","article-title":"FcepsilonR1-expressing nociceptors trigger allergic airway inflammation","volume":"147","author":"Crosson","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2025.118211_bib48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ejmech.2025.118211_bib49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: a multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ejmech.2025.118211_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118211_bib51","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/jidsymp.2013.7","article-title":"The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives","volume":"16","author":"Paus","year":"2013","journal-title":"J. Invest. Dermatol. Symp. Proc."},{"key":"10.1016\/j.ejmech.2025.118211_bib52","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the treatment of alopecia areata","volume":"83","author":"Freitas","year":"2023","journal-title":"Drugs"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T08:01:38Z","timestamp":1762675298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S0223523425009766"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118211","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a novel benzyloxy-terminated scaffold as a potent and selective TYK2 inhibitor for anti-inflammatory therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118211"}}